Earnings per share for the last twelve months: Erasca Inc (ERAS)

ERAS (Erasca Inc) - company brandmark

Erasca, Inc. (ERAS) is implementing comprehensive therapies to block RAS/MAPK pathways, preventing tumor resistance. However, high development costs and the risk of clinical trial failure create financial threats. The company's patent portfolio and the high barriers to entry in the sector serve as a defense. The 12-month net income per share snapshot captures the profitability trend, where the metric value stands at -0.95.

ERAS (Erasca Oncology) Net earnings per one share for the last twelve months history from 07/04/2022 to 11/11/2026

Analytical breakdowns for Erasca Inc (ERAS)

- share price and expert price forecast:
Stock Quotes Erasca, Inc.|ERAS - Analyst Consensus Forecast
- company stock exchange capitalization indicators:
Market Value Erasca, Inc.|ERAS - Value Adjusted for Debt and Cash
- shareholders' equity book value data:
Book Value per Share Erasca|ERAS - Total Stockholders' Equity|Market Capitalization to Book Value Ratio erasca.com|ERAS - Company Assets
- debt obligations and liquidity statistics:
Debt to Equity Erasca, Inc.|ERAS - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Erasca Corp|ERAS - Company Aggregate Debts|Debt to Book Capitalization Ratio Erasca, Inc.|ERAS - Long-Term Debt Volume|Company Short-Term Debts Erasca|Quick Ratio erasca.com
- net income and valuation multiples indicators:
ERAS - Net Profit|Future Profit Erasca, Inc.|ERAS - Company Value to Net Income|Forward P/E Multiple Erasca|ERAS - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Erasca, Inc.|ERAS - Operating profit before amortization|Net earnings per share (EPS TTM) Erasca|ERAS - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months erasca.com|ERAS - Expected net earnings per share growth this year|Earnings growth forecast for next year Erasca, Inc.
Analysis of all company metrics:ERAS - Erasca, Inc.
Mass-produced product of Erasca Inc

For Erasca, Inc. (ERAS), which possesses high scientific authority in oncology, earnings per share over the last four quarters serve as an indicator of the efficiency of clinical trial cost management. This metric is calculated by dividing the total annual net income by the total number of shares, allowing the investor to assess the real profitability of the business, stripped of market noise and volatility.

Competitors of Erasca, Inc.

ONC: Net earnings per share for the last 12 months|HALO - Net earnings per share (EPS TTM)|Revolution Medicines, Inc. (RVMD) - Earnings per share for the last twelve months|Ascentage Pharma Group International - Earnings per share for the trailing year|CGON (CG Oncology Corp) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months UroGen Pharma Corp URGN|Net earnings per share (EPS TTM) BCAX|PSNL - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Delcath Systems DCTH|Earnings per share for the trailing year YMAB|Aura Bio - Net earnings per share (EPS TTM)|CADL - Net earnings per share (EPS TTM)|Accuray Incorporated (ARAY) - Earnings per share for the last twelve months|SLS - Net earnings per share for the last four quarters|ACTU (Actuate Therapeutics) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Citius Oncology Inc. (CTOR)|Net earnings per share (EPS TTM) HURA|Net earnings per share (EPS TTM) Protara Tx (TARA)|Fate Therapeutics, Inc. - Net earnings per share for the last 12 months|Earnings per share for the trailing year WHWK|TScan - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Champions Oncology CSBR|xbiotech.com (XBIT) - Earnings per share for the last twelve months|Earnings per share for the last 12 months CVM|OSTX (OS Therapies Incorporated) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months radiopharmtheranostics.com (RADX)|Net earnings per share for the last 12 months ARTV (Artiva Biotherapeutics, Inc.)|Net earnings per share for the last four quarters adlainortye.com|Net earnings per share (EPS TTM) VERU (Veru Pharma)|Tempest Therapeutics Corp (TPST) - Net earnings per one share for the last twelve months|XLO - Earnings per share for the last twelve months|Earnings per share for the trailing year RENB (Renovaro Inc.)|MURA: Net earnings per share (EPS TTM)|Kairos Pharma (KAPA) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months OnKure Therapeutics, Inc.|CytoMed (GDTC) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) CRIS|Net earnings per share for the last 12 months apollomicsinc.com APLM|Net earnings per share (EPS TTM) THAR (Tharimmune)|Net earnings per share (EPS TTM) Advanced Biomed Inc. ADVB|GNPX - Earnings per share for the last twelve months|CLDI (Calidi Biotherapeutics) - Earnings per share for the last 12 months|SBFM: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Xenetic Biosciences, Inc.|SLRX (Salarius Pharmaceuticals, Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Purple Biotech Ltd PPBT|Earnings per share for the last twelve months American Oncology Network (AONC)|BGNE (BeiGene Ltd) - Earnings per share for the trailing year|Checkpoint Therapeutics - Net earnings per share for the last 12 months|Earnings per share for the trailing year ELEV|iCAD Corp - Net earnings per share (EPS TTM)|Ikena Oncology, Inc. (IKNA) - Net earnings per share for the last 12 months|NTBL (Notable Labs Inc.) - Net earnings per share for the last 12 months|Viracta Therapeutics, Inc. (VIRX) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months MorphoSys AG|NAYA: Earnings per share for the trailing year|Net earnings per share (EPS TTM) AAPGV